KaNDy Therapeutics Ltd.

Nearly three and a half years after being bought by Bayer, Vividion Therapeutics has itself hit the acquisition trial to buy the US precision oncology platform company Tavros Therapeutics. Vividion sa

Bayer AG has made its first filing for elinzanetant, trumpeted as a key growth driver for its pharma division in the coming years, just as Astellas Pharma, Inc. 's rival non-hormonal treatment for m

Bayer AG head of pharmaceuticals research and development Christian Rommel acknowledges that the conglomerate is working its way through a difficult period, but he oversees an R&D pipeline that needs

Astellas Pharma, Inc. is currently ahead in the non-hormonal menopausal relief race but Bayer AG is coming up on the rails after reporting positive results from two late-stage trials for elinzaneta